SPDR Series Trust. Holdings as of Jun 30, 2026, from Form N-PORT.
Share of net assets at the report date, for the whole fund across all share classes.
| Holding | Weight | Value | Shares or units |
|---|---|---|---|
| State Street Global AdvisorsCash or money market | 8.58% | $36.75M | 36,754,275 |
| Definium Therapeutics IncDFTX | 3.09% | $13.23M | 281,317 |
| MBX Biosciences IncMBX | 2.72% | $11.65M | 210,962 |
| Alumis IncALMS | 2.14% | $9.17M | 325,914 |
| AtaiBeckley Inc | 2.13% | $9.11M | 1,729,574 |
| Trevi Therapeutics IncTRVI | 2.12% | $9.10M | 487,893 |
| Enliven Therapeutics IncELVN | 2.09% | $8.97M | 176,696 |
| Amylyx Pharmaceuticals IncAMLX | 2.04% | $8.72M | 485,721 |
| VeraDermics IncMANE | 2.02% | $8.64M | 70,310 |
| Ligand Pharmaceuticals IncLGND | 1.94% | $8.32M | 26,334 |
| Nuvation Bio IncNUVB | 1.89% | $8.11M | 1,427,463 |
| Edgewise Therapeutics IncEWTX | 1.88% | $8.07M | 198,593 |
| Nektar TherapeuticsNKTR | 1.88% | $8.04M | 115,142 |
| Liquidia CorpLQDA | 1.86% | $7.99M | 100,195 |
| Maze Therapeutics IncMAZE | 1.85% | $7.93M | 265,830 |
| Harrow IncHROW | 1.81% | $7.73M | 182,110 |
| EyePoint IncEYPT | 1.77% | $7.58M | 530,232 |
| Amneal Pharmaceuticals IncAMRX | 1.72% | $7.39M | 426,750 |
| Ocular Therapeutix IncOCUL | 1.71% | $7.35M | 748,033 |
| Corcept Therapeutics IncCORT | 1.70% | $7.28M | 83,688 |
| Crinetics Pharmaceuticals Inc | 1.66% | $7.13M | 190,494 |
| Pacira BioSciences IncPCRX | 1.65% | $7.08M | 279,152 |
| Merck & Co IncMRK | 1.65% | $7.05M | 54,900 |
| Indivior Pharmaceuticals IncINDV | 1.64% | $7.04M | 171,638 |
| Elanco Animal Health IncELAN | 1.64% | $7.04M | 285,865 |
| Johnson & JohnsonJNJ | 1.63% | $6.96M | 27,417 |
| Eli Lilly & CoLLY | 1.61% | $6.91M | 5,757 |
| Jazz Pharmaceuticals PLC | 1.60% | $6.86M | 28,473 |
| Collegium Pharmaceutical IncCOLL | 1.59% | $6.80M | 187,866 |
| Bristol-Myers Squibb CoBMY | 1.58% | $6.78M | 117,586 |
| Supernus Pharmaceuticals IncSUPN | 1.57% | $6.74M | 144,999 |
| Royalty Pharma PLC | 1.57% | $6.72M | 119,915 |
| Tarsus Pharmaceuticals IncTARS | 1.57% | $6.72M | 106,709 |
| WaVe Life Sciences Ltd | 1.57% | $6.71M | 1,155,091 |
| Harmony Biosciences Holdings IncHRMY | 1.57% | $6.71M | 184,265 |
| Organon & CoOGN | 1.54% | $6.62M | 488,626 |
| ANI Pharmaceuticals IncANIP | 1.54% | $6.61M | 79,881 |
| Viatris IncVTRS | 1.54% | $6.58M | 414,570 |
| Esperion Therapeutics Inc | 1.54% | $6.58M | 2,082,103 |
| Axsome Therapeutics IncAXSM | 1.52% | $6.50M | 26,541 |
| Innoviva IncINVA | 1.51% | $6.46M | 284,255 |
| BioAge Labs IncBIOA | 1.50% | $6.43M | 262,153 |
| Prestige Consumer Healthcare IncPBH | 1.47% | $6.29M | 133,070 |
| Rapport Therapeutics IncRAPP | 1.44% | $6.16M | 147,854 |
| Pfizer IncPFE | 1.44% | $6.15M | 255,385 |
| Omeros CorpOMER | 1.42% | $6.10M | 640,960 |
| Perrigo Co PLC | 1.42% | $6.08M | 585,303 |
| Xeris Biopharma Holdings IncXERS | 1.39% | $5.97M | 753,307 |
| Zoetis IncZTS | 1.35% | $5.78M | 80,428 |
| Eton Pharmaceuticals IncETON | 1.30% | $5.59M | 154,434 |
Holdings from the fund's latest Form N-PORT; expense ratio (net of fee waivers) from the risk/return summary of its prospectus; fund type from Form N-CEN. Prices are end-of-day closes adjusted for splits; total return also reinvests distributions.